相关实验视频

Updated: Jul 23, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

针对B细胞非霍奇金淋巴瘤的T细胞重定向疗法:最近的进展和未来的方向

David A Russler-Germain^1,2, Armin Ghobadi^1,2

¹Division of Oncology, Washington University School of Medicine, St. Louis, MO, United States.

Frontiers in oncology

|July 19, 2023

概括

在B细胞非霍奇金淋巴瘤 (B-NHL) 治疗方面取得的进展包括抗CD20单克隆抗体,针对CD19的嵌合抗原受体 (CAR) T细胞疗法和T细胞重定向疗法,如双特异性抗体 (BsAbs). 这些创新改善了B-NHL患者的治疗结果.

科学领域:

血液学血液学血液学
免疫学免疫学免疫学
在瘤学瘤学.

背景情况:

B细胞非霍奇金淋巴瘤 (B-NHL) 治疗已经显著发展.
关键的进展是利用B细胞谱系标记物用于向免疫疗法.

研究的目的:

审查T细胞重定向治疗B-NHL的里程碑式发展.
讨论新出现的证据,临床试验的教训和未来的方向.

主要方法:

在过去的二十年中,对治疗方面的进展进行了回顾.
免疫疗法的分析,包括单克隆抗体,CAR T细胞和双特异性抗体 (BsAbs).

主要成果:

抗CD20单克隆抗体 (rituximab) 改善了B-NHL的结局.
化学抗原受体 (CAR) T细胞疗法转化复发/耐药DLBCL治疗.
包括BsAbs在内的T细胞重定向疗法在重度预处理的B-NHL中表现出显著的活性.

结论:

T细胞重定向疗法代表了B-NHL治疗的重大进步.
目前正在进行的试验正在探索新型免疫疗法的组合,以提高疗效.
未来的方向侧重于优化T细胞对各种B-NHL亚型的参与策略.

关键词:

一个T细胞细胞.抗体是一种抗体.两种类型的两种类型的参与者参与者参与者免疫疗法免疫疗法淋巴瘤淋巴瘤是什么

更多相关视频

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.